Our PiNACLE trial is recruiting patients with aggressive B-cell non-Hodgkin lymphoma. Learn more about the trial here or contact us at clinicaltrials@lyell.com
Enhancing the Extraordinary
Our Story
Founder's Vision
Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business.
Our Science
Technology designed to generate CAR T cells that deliver more durable outcomes for patients with cancer.
Our Pipeline
Our pipeline targets hematologic malignancies and solid tumors with significant unmet medical need.
Dedicated to Patients
An unwavering focus on science guides our mission to deliver transformative CAR T-cell therapies for patients with solid tumors and hematologic malignancies.
Learn MoreLatest News
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational
View All NewsJoin Our Team
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.
Join our team of ambitious Lyellites who are committed to defeating cancer through innovation.
See Open Positions